{"id":51628,"date":"2022-12-06T17:02:22","date_gmt":"2022-12-06T16:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/"},"modified":"2022-12-06T17:02:22","modified_gmt":"2022-12-06T16:02:22","slug":"rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/","title":{"rendered":"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5261879\/rare-disease-genetic-testing-market-share-size?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6l85wj&amp;utm_campaign=1785108+-+Rare+Disease+Genetic+Testing+Market+Report+2022%3A+Advancements+Such+as+NGS+and+Microarray+Testing+Drive+Sector&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe global rare disease genetic testing market size is expected to reach USD 2,414.90 million by 2030 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\n<\/p>\n<p>\nIncreasing technological advancements, including NGS and microarray, are prominent factors responsible for the market&#8217;s growth. Also, the existence of Rare Diseases Clinical Research Network (RDCRN), an NIH-funded research network of 23 active research groups focused on the diagnosis &amp; treatment of disorders, is anticipated to impact the industry positively. Furthermore, the decline in sequencing prices has shifted the attention to testing rare diseases, which has influenced the adoption of NGS, resulting in the market&#8217;s growth.\n<\/p>\n<p>\nTranslational research and genomic technologies play a crucial role in accelerating the investigation and identification of new mutations, which aid in market expansion. Due to numerous translational research activities in this field, genetic testing in disease diagnostics is expected to rise rapidly throughout the projection period.\n<\/p>\n<p>\nAn increase in patient registry for rare diseases and development of new products to treat rare diseases are stimulating the growth of the market. The market is expected to grow as the number and quality of available registries continue to expand. So advanced data collection and interpretation technologies that can be used in clinical practices improve. An increasing number of patients undergoing disease testing, as well as increased government assistance, will fuel several new opportunities for market growth.\n<\/p>\n<p>\n<strong>Rare Disease Genetic Testing Market Report Highlights<\/strong>\n<\/p>\n<ul>\n<li>\nEndocrine and metabolism disease witnessed the largest market share in 2021 due to the growing number of patients with Cushing&#8217;s syndrome.\n<\/li>\n<li>\nThe next-generation sequencing segment acquires significant market share due to increasing medical acceptance of whole exome sequencing-based gene tests.\n<\/li>\n<li>\nMolecular genetic test segment is anticipated to hold considerable market share during the forecast period due to advanced testing technologies such as genome sequencing, which is affordable.\n<\/li>\n<li>\nResearch labs &amp; CROs accounted largest market share in 2021 due to a large number of genetic tests performed in research laboratories and CROs.\n<\/li>\n<li>\nNorth America dominated the market in 2021 due to the high prevalence of rare diseases and the abundance of registries in this region.\n<\/li>\n<\/ul>\n<p>\n<strong>The publisher has segmented the rare disease genetic testing market report based on disease type, technology, specialty, end-use, and regions:<\/strong>\n<\/p>\n<p>\n<strong>Rare Disease Genetic Testing, Disease Type Outlook (Revenue &#8211; USD Million, 2018 &#8211; 2030)<\/strong>\n<\/p>\n<ul>\n<li>\nNeurological disease\n<\/li>\n<li>\nImmunological disorders\n<\/li>\n<li>\nHematology diseases\n<\/li>\n<li>\nEndocrine and metabolism diseases\n<\/li>\n<li>\nCancer\n<\/li>\n<li>\nMusculoskeletal disorders\n<\/li>\n<li>\nCardiovascular disorders\n<\/li>\n<li>\nDermatological disease\n<\/li>\n<li>\nOthers\n<\/li>\n<\/ul>\n<p>\n<strong>Rare Disease Genetic Testing, Technology Outlook (Revenue &#8211; USD Million, 2018 &#8211; 2030)<\/strong>\n<\/p>\n<ul>\n<li>\nNext-generation sequencing\n<\/li>\n<li>\nWhole Exome\n<\/li>\n<li>\nWhole Genome\n<\/li>\n<li>\nArray Technology\n<\/li>\n<li>\nPCR-based testing\n<\/li>\n<li>\nFISH\n<\/li>\n<li>\nSanger Sequencing\n<\/li>\n<li>\nKaryotyping\n<\/li>\n<\/ul>\n<p>\n<strong>Rare Disease Genetic Testing, Specialty Outlook (Revenue &#8211; USD Million, 2018 &#8211; 2030)<\/strong>\n<\/p>\n<ul>\n<li>\nMolecular genetic tests\n<\/li>\n<li>\nChromosomal genetic tests\n<\/li>\n<li>\nBiochemical genetic tests\n<\/li>\n<\/ul>\n<p>\n<strong>Rare Disease Genetic Testing, End-Use Outlook (Revenue &#8211; USD Million, 2018 &#8211; 2030)<\/strong>\n<\/p>\n<ul>\n<li>\nResearch Lab and CROs\n<\/li>\n<li>\nHospitals and Clinics\n<\/li>\n<li>\nDiagnostic Laboratories\n<\/li>\n<\/ul>\n<p>\n<strong>Rare Disease Genetic Testing, Regional Outlook (Revenue &#8211; USD Million, 2018 &#8211; 2030)<\/strong>\n<\/p>\n<ul>\n<li>\nNorth America\n<\/li>\n<li>\nU.S\n<\/li>\n<li>\nCanada\n<\/li>\n<li>\nEurope\n<\/li>\n<li>\nGermany\n<\/li>\n<li>\nUK\n<\/li>\n<li>\nFrance\n<\/li>\n<li>\nItaly\n<\/li>\n<li>\nSpain\n<\/li>\n<li>\nRussia\n<\/li>\n<li>\nNetherlands\n<\/li>\n<li>\nAsia Pacific\n<\/li>\n<li>\nChina\n<\/li>\n<li>\nIndia\n<\/li>\n<li>\nJapan\n<\/li>\n<li>\nSouth Korea\n<\/li>\n<li>\nIndonesia\n<\/li>\n<li>\nMalaysia\n<\/li>\n<li>\nLatin America\n<\/li>\n<li>\nArgentina\n<\/li>\n<li>\nBrazil\n<\/li>\n<li>\nMexico\n<\/li>\n<li>\nMiddle East &amp; Africa\n<\/li>\n<li>\nUAE\n<\/li>\n<li>\nSaudi Arabia\n<\/li>\n<li>\nIsrael\n<\/li>\n<li>\nSouth Africa\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Introduction<\/strong>\n<\/p>\n<p>\n<strong>2. Executive Summary<\/strong>\n<\/p>\n<p>\n<strong>3. Research Methodology<\/strong>\n<\/p>\n<p>\n<strong>4. Global Rare Disease Genetic Testing Market Insights<\/strong>\n<\/p>\n<p>\n<strong>5. Global Rare Disease Genetic Testing Market, by Technology<\/strong>\n<\/p>\n<p>\n<strong>6. Global Rare Disease Genetic Testing Market, by Specialty<\/strong>\n<\/p>\n<p>\n<strong>7. Global Rare Disease Genetic Testing Market, by Disease Type<\/strong>\n<\/p>\n<p>\n<strong>8. Global Rare Disease Genetic Testing Market, by End-use<\/strong>\n<\/p>\n<p>\n<strong>9. Global Rare Disease Genetic Testing Market, by Geography<\/strong>\n<\/p>\n<p>\n<strong>10. Competitive Landscape<\/strong>\n<\/p>\n<p>\n<strong>11. Company Profiles<\/strong>\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\n3billion Inc.\n<\/li>\n<li>\nAmbry Genetics\n<\/li>\n<li>\nArtemis DNA\n<\/li>\n<li>\nArup Laboratories\n<\/li>\n<li>\nBaylor Genetics\n<\/li>\n<li>\nCentogene N.V.\n<\/li>\n<li>\nColor Genomics Inc.\n<\/li>\n<li>\nCoopersurgical Inc.\n<\/li>\n<li>\nEurofins Scientific\n<\/li>\n<li>\nFulgent Genetics Inc.\n<\/li>\n<li>\nGenomenon\n<\/li>\n<li>\nHealth Network Laboratories\n<\/li>\n<li>\nInvitae Corp.\n<\/li>\n<li>\nLaboratory Corporation of America Holdings\n<\/li>\n<li>\nMacrogen Inc.\n<\/li>\n<li>\nMyriad Genetics Inc.\n<\/li>\n<li>\nOpko Health Inc.\n<\/li>\n<li>\nPerkin Elmer Inc.\n<\/li>\n<li>\nPreventionGenetics\n<\/li>\n<li>\nProgenity Inc.\n<\/li>\n<li>\nQuest Diagnostics Inc.\n<\/li>\n<li>\nRealm IDX Inc.\n<\/li>\n<li>\nStrand Life Sciences.\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5261879\/rare-disease-genetic-testing-market-share-size?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=6l85wj&amp;utm_campaign=1785108+-+Rare+Disease+Genetic+Testing+Market+Report+2022%3A+Advancements+Such+as+NGS+and+Microarray+Testing+Drive+Sector&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/g3bh4a<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;&#x74;&#111;&#x3a;p&#x72;&#x65;&#115;&#x73;&#64;&#x72;&#x65;&#115;&#x65;a&#x72;&#x63;&#104;&#x61;n&#x64;&#x6d;&#97;&#x72;k&#x65;&#x74;&#115;&#x2e;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#101;&#115;s&#x40;&#x72;&#x65;&#115;ea&#x72;&#x63;&#104;&#97;n&#x64;&#x6d;&#x61;&#114;ke&#x74;&#x73;&#46;&#99;o&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global rare disease genetic testing market size is expected to reach USD 2,414.90 million by 2030 according to a new &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51628","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global rare disease genetic testing market size is expected to reach USD 2,414.90 million by 2030 according to a new ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-06T16:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-12-06T16:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/\"},\"wordCount\":748,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005839\\\/en\\\/1656663\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/\",\"name\":\"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005839\\\/en\\\/1656663\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-12-06T16:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005839\\\/en\\\/1656663\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221206005839\\\/en\\\/1656663\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global rare disease genetic testing market size is expected to reach USD 2,414.90 million by 2030 according to a new ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-06T16:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector &#8211; ResearchAndMarkets.com","datePublished":"2022-12-06T16:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/"},"wordCount":748,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/","name":"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/21\/logo.jpg","datePublished":"2022-12-06T16:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221206005839\/en\/1656663\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rare-disease-genetic-testing-market-report-2022-advancements-such-as-ngs-and-microarray-testing-drive-sector-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51628"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51628\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}